Response to comments on: “The Influence of Wall Stress on AAA Growth and Biomarkers”  by Speelman, L. et al.
Correspondence 797Response to comments on: “The Influence of
Wall Stress on AAA Growth and Biomarkers”Dear Editor,
I thank Dr. Georgakarakos and colleagues for their letter
in response to our article. We attempted to predict AAA
growth based on relative wall stress. We found a lower
growth rate for the group of AAAs with a relative low
wall stress.1 However, AAA growth is most likely a multi-
factorial phenomenon, possibly including the effects of
flow through the AAA. It is known that AAAs grow faster
when they increase in size. Also the amount of thrombus
grows, narrowing the flow lumen to a comparable size as
the healthy aorta, only the flow lumen is more tortuous
in AAAs. Additionally, the endothelial cells normally
covering the vessel wall are destroyed and can therefore
not respond to shear stresses induced by secondary flows.
Our group previously developed FSI models of AAAs2 and,
among others, we will further investigate the relation
between aneurysmal flow, thrombus and AAA growth.
Additionally we will evaluate these models to study the
relation between wall stress, flow effects, circulating
biomarkers and AAA growth in a larger patient
population.
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Comment on “Variations in the Pharmacological
Management of Patients Treated with Carotid
Endarterectomy: A Survey of European
Vascular Surgeons”Dear Editor,
We noted with interest the persistent variation in perioper-
ative Clopidogrel management at the time of carotid endar-
terectomy (CEA) as documented by Hamish et al (Eur J Vasc
Endovasc Surg 2009;38:402e7). The authors demonstrate
that 43% and 55% of surgeons queried would stop Clopidogrel
prior toCEA for both symptomatic and asymptomatic patients
respectively.
Furthermore, the authors noted that over 49% of
surgeons would stop Clopidogrel more than 7 days prior to
surgery, irrespective of a patient’s symptomatic status.
Presumably, these clinical biases reflect a presumption that
Clopidogrel is associated with increased serious bleeding
complications at the time of CEA. Further, in symptomatic
patients, it suggests that surgeons who stop Clopidogrel are
more concerned about operative bleeding than about
antiplatelet efficacy perioperatively.
In a recent study conducted by the Vascular Study Group
of New England, we evaluated 4587 CEAS performed by 66
surgeons in the United States. Though our analysis focusedDOI of original article: 10.1016/j.ejvs.2009.07.001.
